Biosimilars in 2018: EU doctors’ perceptions of RA drug market
Published in pharmaphorum October 2015 by Laurent Chanroux
Physicians in Europe's Big 5 think current market leaders will continue to lead, with biosimilars making the greatest inroads in the field up to 2018, if clearer guidance on efficacy and safety is provided.
A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they currently treat their patients and what they expect to be doing in 2018. The findings suggest that the market leaders can breathe easy, for the moment at least.
Register to find out how a combination of virtual patients and artificial intelligence can help you to better understand physicians’ decision making processes. Research Partnership
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space. Research Partnership
Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers Research Partnership